PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “MONILIASIS, ORAL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1978

[The occurrence of nappy rash at a children's hospital and its treatment with Canesten (author's transl)].

An unselected, mycologically-controlled trial was conducted at the University Children's Hospital of Graz on the treatment of nappy rash by the topical application of Canesten (clotrimazole), a broad-spectrum mycotic in the form of a 1% cream. 56 children, ranging in age from 3 weeks to 41/2 years, were treated for thrush, principally located in the genital area. Only some of the children were admitted primarily on account of the oral and/or perianal moniliasis. The majority of the children were hospitalized for some other reason and thrush was diagnosed as an accompanying condition. Candida albicans proved to be the most frequent pathogenic organism. The results of therapy were judged according to mycological and clinical criteria. The mycological findings became negative in 54 out of the 56 children. Clinical improvement was apparent in all cases between the 5th and 10th day of therapy; complete recovery occurred between the 5th and 25th day, depending on the extent and localization of the moniliasis. One child showed improvement in, but not recovery from the disease, because therapy was interrupted on premature discharge from hospital. Therapy was unsuccessful in the remaining child, although slight improvement occurred. Tolerance was good in all patients on application of Canesten cream thrice daily.

Administration, Topical↗
PubMedDate not supplied

[Hypoparathyroidism and Addison's disease with moniliasis: report of two cases in childhood (author's transl)].

Two pediatric cases are described presenting a conjunction of Addison's disease and hypoparathyroidism. One of the two cases also exhibits moniliasis of the oral cavity (Whitaker's disease). A full report is given of the symptoms and of the laboratory analyses which have motivated the diagnosis, and of the endocrinological function tests which were intended to confirm the diagnosis. The clinical process and the therapeutic criteria adopted are subsequently reported. A discussion follows focusing on the possible causes of the coexistence of the immunological defect and of the endocrinous deficiencies which are typical of the syndrome. Pathogenetic priority is attributed to the immunological defect which induces a autoimmune lesion of the endocrinous glands concerned.

Addison Disease↗
PubMed2001

Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria.

Recently, new broad spectrum carbapenem has been investigated on a world-wide scale for the treatment of moderate to severe infections. In the neonatal intensive care units the extensive use of third generation cephalosporins for therapy of neonatal sepsis may lead to rapid emergence of multiresistant gram-negative organisms. We report the use of meropenem in 35 infants with severe infections due to Acinetobacter baumanii and Klebsiella pneumoniae. All gram negative bacteria were resistant to ampicillin, amoxicillin, ticarcilin, cefazoline, cefotaxime, ceftazidime, ceftriaxone and aminoglycosides. Eighty two percent of the cases (29/35) were born prematurely. Assisted ventilation was needed in 85.7% (30/35). All infants deteriorated during their conventional treatment and were changed to meropenem monotherapy. Six percent (2/35) died. The incidence of drug-related adverse events (mostly a slight increase in liver enzymes) was 8.5%. No adverse effects such as diarrhea, vomiting, rash, glossitis, oral or diaper area moniliasis, thrombocytosis, thrombocytopenia, eosinophilia and seizures were observed. At the end of therapy, overall satisfactory clinical and bacterial response was obtained in 33/35 (94.3%) of the newborns treated with meropenem. Clinical and bacterial response rates for meropenem were 100% for sepsis and 87.5% for nosocomial pneumonia. This report suggests that meropenem may be a useful antimicrobial agent in neonatal infections caused by multiresistant gram negative bacilli. Further studies are needed to confirm these results: Meropenem, newborn, sepsis and nosocomial infection.

Acinetobacter Infections↗
PubMed1954

Anogenital moniliasis.

Thirty cases of anogenital moniliasis were studied. Only five followed oral use of broad spectrum antibiotics. Although anogenital pruritus commonly follows the use of such drugs, it is rarely proved to be moniliasis, which is clinically diagnosed by symptoms of intertriginous denudation with satellite vesicopustules or the presence of cheesy, grossly detachable plaques. The diagnosis may be confirmed by microscopic observation of delicate hyphae and clusters of spores, or of chlamydospores on corn meal agar. One per cent aqueous gentian violet, 0.1 per cent gentian violet jel, or locally applied mercurials are the most effective forms of treatment, but effort must also be directed against predisposing factors (obesity, hyperhidrosis, oral or local use of broad spectrum antibiotics, diabetes and pregnancy).

Anal Canal↗
PubMed1963

[MONILIASIS].

Explore the source record for details and available documents.

Addison Disease↗
PubMed1975

Monilial esophagitis.

A case of monilial esophagitis, developing in a diabetic patient treated with gentamicin for Escherichia coli septicemia, is described. The esophagogram was normal and the diagnosis was confirmed by fiberoptic esophagoscopy and biopsy examination. The patient responded to oral nystatin. The literature on esophageal moniliasis is reviewed.

Biopsy↗
PubMed1966

Moniliasis.

Explore the source record for details and available documents.

Candidiasis, Oral↗
PubMed1952

Moniliasis.

Explore the source record for details and available documents.

Animals↗
PubMed1966

Moniliasis.

Explore the source record for details and available documents.

Amphotericin B↗
PubMed2002

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.

OBJECTIVE: This study aimed to compare the efficacy and safety of oral gemifloxacin, an enhanced-affinity quinolone, with sequential therapy with IV ceftriaxone followed by oral cefuroxime (with or without a macrolide) in patients hospitalized for community-acquired pneumonia (CAP). METHODS: A randomized, open-label, multicenter study comprised adults hospitalized with a clinical and radiologic diagnosis of CAP. Patients were randomized 1:1 to receive either (1) oral gemifloxacin 320 mg once daily (7-14 days); or (2) IV ceftriaxone 2 g once daily (1-7 days) followed by oral cefuroxime 500 mg twice daily (1-13 days) for a total of < or = 14 days. Patients receiving ceftriaxone/cefuroxime were allowed concomitant macrolide treatment. RESULTS: A total of 345 patients were randomized, of whom 341 received at least 1 dose of study medication (gemifloxacin, 169/172; ceftriaxone/cefuroxime, 172/173). Clinical success rates in the clinically evaluable (CE) population at follow-up (day 21-28 post-therapy), the primary end point, were 92.2% (107/116) for gemifloxacin and 93.4% (113/121) for ceftriaxone/cefuroxime (treatment difference, -1.15; 95% CI, -7.73 to 5.43). In patients in Fine risk classes IV and V, the clinical success rate was 87.0% (20/23) for gemifloxacin versus 83.3% (20/24) for ceftriaxone/cefuroxime. No difference in clinical response at follow-up was noted based on macrolide use. Bacteriologic success rates at follow-up in the bacteriologically evaluable (BE) population were 90.6% (58/64) for gemifloxacin and 87.3% (55/63) for ceftriaxone/cefuroxime (treatment difference 3.32; 95% CI, -7.57 to 14.21). The clinical success rate in bacteremic patients at follow-up (BE population) was 100.0%. Both treatments were generally well tolerated. The frequency and types of adverse events were similar between the 2 groups. The most common treatment-related adverse events with gemifloxacin were diarrhea, liver-function adverse events, and rash; with ceftriaxone/cefuroxime, they were diarrhea, elevated hepatic-enzyme activity, and moniliasis. CONCLUSION: The clinical efficacy and tolerability of oral gemifloxacin 320 mg once daily were similar to those of IV ceftriaxone followed by oral cefuroxime (with or without a macrolide) in the treatment of adult patients hospitalized with moderate to severe CAP. Both treatments were effective in bacteremic patients and those at increased risk of mortality.

Administration, Oral↗